European journal of rheumatology最新文献

{"title":"First Report of the Immunogenicity of an Inactivated SARS-CoV-2 (COVID-19) Vaccine in Iranian Patients with Autoimmune Diseases.","authors":"Parmida Aminzadeh, Ava Hashempour, Shahab Falahi, Farimah Safari, Maryam Feili, Azra Kenarkoohi","doi":"10.5152/eurjrheum.2025.24057","DOIUrl":"https://doi.org/10.5152/eurjrheum.2025.24057","url":null,"abstract":"<p><p>Background: Infectious diseases are responsible for considerable morbidity and mortality worldwide, and coronavirus disease 2019 (COVID-19) is one of these infections. Because of the substantial bur- den on the healthcare system, considerable efforts have been made to immunize the population against severe acute respiratory syndrome coronavirus 2 through vaccination. However, there are considerations regarding the efficacy of vaccines in autoimmune patients. The current study revealed the immunogenicity of inactivated COVID-19 vaccines among the Iranian population with rheumatic diseases. Methods: As the first report from Iran, in this descriptive cross-sectional study, 196 patients were sam- pled; 98 of whom had an autoimmune disease and 98 of whom served as controls. Blood samples were collected and tested with IgM and IgG ELISA kits for COVID-19 antibody (Ab) levels. Some demo- graphic characteristics were recorded. Results: This study revealed an Ab response after inactivated COVID-19 vaccination among 196 par- ticipants, including 98 healthy individuals and 98 autoimmune patients. Our analysis revealed that the case group had a profoundly lower percentage of IgG- and IgM-positive individuals, at 37.7% and 13.2%, respectively, than the control group, which had significantly greater percentages of IgG and IgM Abs, at 86.7% and 65.3%, respectively. Conclusion: Individuals with autoimmune conditions, especially women, presented considerable decreases in IgG levels after vaccination with the inactivated COVID-19 vaccine. It seems that those with autoimmune disorders may experience immune system fatigue, leading to lower Ab levels fol- lowing COVID-19 vaccination. Several potential factors, such as the use of immunosuppressive medi- cations, could explain the reduced Ab response after COVID-19 vaccination. As a result, individuals with compromised immune systems, including those with autoimmune disorders, should be closely monitored and prioritized for additional COVID-19 vaccine doses to improve protection. Furthermore, the possible effects of repeated vaccinations on immune exhaustion and reduced defense against microbial infections highlight the need for further research in this patient population. It can be con- cluded that special vaccine protocols for all kinds of vaccinations should be approved for patients with autoimmune diseases.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"12 2","pages":"1-6"},"PeriodicalIF":1.3,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bromocriptine in Rheumatic Diseases: A Review.","authors":"Jozélio Freire de Carvalho, Ana Tereza Amoedo Martinez","doi":"10.5152/eurjrheum.2025.24080","DOIUrl":"https://doi.org/10.5152/eurjrheum.2025.24080","url":null,"abstract":"<p><p>Hyperprolactinemia is frequent in rheumatic diseases. Bromocriptine (BRC) is an antagonist of pro- lactin and was studied in a few rheumatic diseases with controversial results. The aim of the present study was to review articles on BRC in rheumatic diseases. Articles on lupus, rheumatoid arthritis, pso- riatic arthritis (PsA), and reactive arthritis were found. Fourteen articles were found. In lupus, 5 articles evaluated BRC in a 2.5-7.5 mg/day dosage. The follow-up varied from 6 to 14 months. They showed improvement in lupus disease activity (Lupus Disease Activity Index or Lupus activity measure scores) in 4/5; a trend was verified in another article, 1/5, and one study evaluated improvement in the mood of the systemic lupus erythematosus patients. In RA, there are 4 articles with 119 patients. The BRC dosage ranged from 5 mg/day to 10 mg TID. About 2/4 of the articles showed improvements [morn- ing stiffness and Health Assessment Questionnaire (HAQ)], and 2/4 did not show any difference. Regarding PsA and reactive arthritis, 5 articles with 43 patients were found. The BRC dose varied from 2.5 to 30 mg/day. All studies showed improvements of the studied diseases. Side effects were mild and infrequent. In conclusion, BRC seems to be efficacious in a few rheumatic diseases (lupus, PsA, RA, and Reiter's), with mild side effects. Future studies with a larger number of participants and in other rheumatic diseases are needed.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"12 2","pages":"1-5"},"PeriodicalIF":1.3,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plantar Fibromatosis/Fascitis in Ankylosing Spondylitis: Why/Where to Inject?","authors":"Berkay Yalçınkaya, Ahmet Furkan Çolak, Murat Kara, Levent Özçakar","doi":"10.5152/eurjrheum.2025.24112","DOIUrl":"10.5152/eurjrheum.2025.24112","url":null,"abstract":"","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"12 2","pages":"1-2"},"PeriodicalIF":1.3,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144150029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construct Validity and Reliability of the 2-Minute Step Test in Patients with Fibromyalgia.","authors":"Büşra Şirin Ahısha, Nurdan Paker, Fatma Nur Kesiktaş, Derya Buğdaycı, Yelda Soluk Özdemir","doi":"10.5152/eurjrheum.2025.24051","DOIUrl":"10.5152/eurjrheum.2025.24051","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was primarily to assess the validity and reliability of the 2-minute step test (2MST) in patients with fibromyalgia; and secondly, to explore its relationship with the 2-minute walk test (2MWT), the 6-minute walk test (6MWT), as well as fatigue severity and quality of life.</p><p><strong>Methods: </strong>This cross-sectional study involved 55 female patients aged 18-65 diagnosed with fibromyalgia according to the American College of Rheumatology 2010 Diagnostic Criteria. Pain intensity was measured using the Visual Analog Scale, quality of life impact was assessed with the Fibromyalgia Impact Questionnaire, and fatigue severity was evaluated using the Fatigue Severity Scale. Patients underwent initial assessments using the 2MST, 2MWT, and 6MWT. Test-retest reliability of the 2MST was determined with a 7-day interval between assessments.</p><p><strong>Results: </strong>The study included a cohort of participants with an average age of 45.3 ± 7.7 years. The mean score for the 2MST was 51.9 ± 15.6, with a second 2MST yielding a mean score of 56.1 ± 16.4. The reliability of the 2MST was found to be good (ICC=0.925) in patients with fibromyalgia. The 2MSTexhibited significant correlations with the 2MWT (ρ=0.633) and 6MWT (ρ= 0.703).</p><p><strong>Conclusion: </strong>In conclusion, this study demonstrates that the 2MST is a reliable tool for evaluating exercise capacity in individuals with fibromyalgia, showing a negative association with age and pain severity.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"12 2","pages":"1-5"},"PeriodicalIF":1.3,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Assessment of Perceived Stress, Anxiety, Depression, Insomnia, Sleep Quality, and Drug Adherence in Patients with Systemic Lupus Erythematosus During the COVID-19 Pandemic.","authors":"Kardelen Gokmen, Dilek Barutcu Atas, Murat Tugcu, Arzu Velioglu, Hakki Arikan, Fatma Alibaz Oner, Haner Direskeneli, Serhan Tuglular, Ebru Asicioglu","doi":"10.5152/eurjrheum.2025.23108","DOIUrl":"10.5152/eurjrheum.2025.23108","url":null,"abstract":"<p><strong>Background: </strong>Pandemics can increase psychosocial distresses. We evaluated both medication nonadherence and the incidence of perceived stress, anxiety, depression, sleep quality, and insomnia during the coronavirus disease 2019 (COVID-19) pandemic in systemic lupus erythematosus (SLE) patients.</p><p><strong>Methods: </strong>A total of 211 participants, including 160 SLE patients and 51 healthy volunteers, were included. Questionnaire of Medication Adherence Reporting Scale (MARS-5), Perceived Stress Scale (PSS), Hospital Anxiety and Depression Scale (HADS-A, HADS-D), Pittsburgh Sleep Quality Index (PSQI), and Insomnia Severity Index (ISI) were assessed. Perceived stress related to the COVID-19 pandemic and its associations were investigated.</p><p><strong>Results: </strong>The mean age of patients was 41.85±12.97 years. Fifty-nine (36.9%) patients had high perceived stress, 16 (10.0%) had anxiety, 45 (28.1%) had depression, 77 (48.1%) had poor sleep quality, and 62 (38.8%) patients had insomnia. Perceived Stress Scale (23.64 ± 7.86 vs. 19.73 ± 4.80, P=.001), HADS-D (5.60 ± 3.40 vs. 4.08 ± 2.21, P=.003), PSQI (6.31 ± 3.62 vs. 4.43 ± 2.20, P=.001), and ISI (6.81 ± 4.98 vs. 4.53 ± 2.83, P=.002) were higher in the patient group. The presence of anxiety, depression, poor sleep quality, and insomnia was higher in patients with high PSS. High PSS was correlated with HADS-A, HADS-D, PSQI, and ISI. Medication non-adherence was detected in 79 (49.4%) of patients. Regression analysis revealed that high perceived stress is an independent predictor of depression [Exp(β) 95% CI: 1.488 (1.245-1.779), P < .001], and anxiety [Exp(β) 95% CI: 1.235 (1.026-1.487), P=.026].</p><p><strong>Conclusion: </strong>Systemic lupus erythematosus patients demonstrated increased levels of perceived stress, depression, poor sleep quality and insomnia compared to the healthy population during the COVID19 pandemic. Systemic lupus erythematosus patients with high perceived stress had more depression, anxiety, poor sleep quality, and insomnia than those without. Furthermore, high perceived stress was associated with depression and anxiety.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"12 2","pages":"1-7"},"PeriodicalIF":1.3,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060183/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mendelian Randomization Analysis Reveals the Causal Relationships Between Autoimmune Diseases and Idiopathic Thrombocytopenic Purpura and the Mediating Role of Immune Cells.","authors":"Kaiqing Yan, Lin Sun, Wenyu Gao, Qianqian Cui, Hongxiu Liu, Yun Tian, Siyu Gao, Yanping Ma","doi":"10.5152/eurjrheum.2025.24100","DOIUrl":"10.5152/eurjrheum.2025.24100","url":null,"abstract":"<p><strong>Background: </strong>Idiopathic thrombocytopenic purpura (ITP) is related to multiple autoimmune diseases clinically, yet the causal relationship remains unclear. This study employed Mendelian randomization (MR) to explore the genetic causal relationship between autoimmune diseases and ITP and potential mediators in the European population.</p><p><strong>Methods: </strong>Summary statistics of 10 common autoimmune diseases and ITP were extracted for analysis. Bidirectional two-sample MR and two-step MR were conducted.</p><p><strong>Results: </strong>Multiple sclerosis (MS, inverse variance weighted [IVW]: odds ratio (OR)=5.840E+16, false discovery rate (FDR)=0.049), celiac disease (CeD, IVW: OR=1.173, FDR=0.023), systemic lupus erythematosus (SLE, IVW: OR=1.068, FDR=0.049), and autoimmune hyperthyroidism (AIH, IVW: OR=1.265, FDR=0.037) are risk factors for ITP. Rheumatoid arthritis (RA, IVW: OR=1.112, FDR=0.055) may be a potential risk factor. Crohn's disease (CD, IVW: OR=0.816, FDR=0.049), ulcerative colitis (UC, IVW: OR=0.709, FDR=0.042), and psoriasis (PsO, IVW: OR=1.690E - 04, FDR=0.042) are protective factors. No clear causal relationship between ankylosing spondylitis (AS, IVW: OR=1.016, FDR=0.553) and type 1 diabetes mellitus (T1DM, IVW: OR=1.035, FDR=0.577) and ITP. Immune cells act as mediators between CeD and ITP and CD and ITP.</p><p><strong>Conclusion: </strong>This study clarified the relationship between some autoimmune diseases and ITP and the mediating role of immune cells.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"12 1","pages":"1-7"},"PeriodicalIF":1.3,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can the Early Warning Score (ANDC) Predict Tocilizumab Efficacy in Patients with COVID-19 Cytokine Storm?","authors":"Özlem Kılıç, Duygu Tecer, Mehmet Nur Kaya, Muhammet Çınar, Sedat Yılmaz","doi":"10.5152/eurjrheum.2025.24048","DOIUrl":"10.5152/eurjrheum.2025.24048","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study is to assess the effectiveness of the Early Warning Score [ANDC (age (A), neutrophil-to-lymphocyte ratio (NLR (N)), D-dimer (D), and CRP (C)] in predicting the treatment response in patients receiving tocilizumab for Coronavirus Disease 2019 (COVID-19)-related cytokine storm.</p><p><strong>Methods: </strong>A retrospective review of medical records was conducted for patients treated with tocili- zumab for a cytokine storm related to COVID-19 between April 1, 2020, and April 1, 2021. Patient demographics, clinical characteristics, and laboratory parameters within 24 hours before tocilizumab were recorded. 1.14 × (age - 20) (years) + 1.63 × NLR + 5.00 × D-dimer (mg/L) + 0.14 × C-reactive protein (CRP) (mg/L) was used as the formula for the ANDC score. The study population was divided into 2 groups: those who died within 28 days of receiving tocilizumab and those who recovered. A comparative analysis was conducted.</p><p><strong>Results: </strong>Within 28 days of tocilizumab treatment, 59 (35.32%) patients died. In comparison with living patients, deceased patients exhibited considerably higher levels of interleukin (IL)-6, lactate dehydro- genase (LDH), ANDC score, and CRP (P < .05). Lactate dehydrogenase was an independent predictor of response to tocilizumab treatment (P < .001) in a multivariate logistic regression analysis. In patients who did not receive steroid therapy before tocilizumab treatment, the ANDC score had the highest area under the curve (AUC). The optimal cut-off value was determined to be 92.56, with a sensitivity of 91.67% and a specificity of 60.61% (P < .001). In patients receiving steroids before tocilizumab, LDH had the highest AUC. The optimal cut-off value was 484.5 U/L (P < .001).</p><p><strong>Conclusion: </strong>Lactate dehydrogenase was identified as an independent predictor of response to tocili- zumab treatment. The ANDC score showed the highest AUC value in steroid-naïve patients before tocilizumab, whereas LDH showed the highest AUC value in patients receiving steroids before tocili- zumab. Both the ANDC score and LDH levels show potential as valuable tools to guide treatment decisions.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"12 1","pages":"1-6"},"PeriodicalIF":1.3,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Factors Related to Work Productivity and Disease Costs in Patients with Ankylosing Spondylitis.","authors":"Mine Aydan Cenberoğlu, Ilhan Sezer","doi":"10.5152/eurjrheum.2025.22118","DOIUrl":"10.5152/eurjrheum.2025.22118","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;To examine the effect of ankylosing spondylitis (AS) on work productivity, work instability and absenteeism, and the cost to the national economy of the disease.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This cross-sectional study included 100 AS patients from the outpatient rheumatology clinic at Akdeniz University Hospital who met the 1984 modified New York criteria. Annual direct and indirect care costs of the AS patients were recorded, along with their sociodemographic data and clinical characteristics. Direct costs were based on reimbursements from the National Social Security Institution, while indirect costs were estimated using the human capital approach to account for productivity loss and absenteeism related to income, reflecting the disease's economic impact on work capabilities. The work-related outcomes were evaluated with the Work Productivity and Activity Impairment-Spondyloarthropathy (WPAI-SpA) and Ankylosing Spondylitis Work Instability Scale (AS-WIS). Pearson correlation analysis was applied to determine the relationships between quanti- tative variables, while the Chi-square test or Fisher's exact test was used for relationships between qualitative variables. To assess the effects of independent variables on work productivity impairment, activity, and work instability, multivariate linear and logistic regression methods were used.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among the 87 working AS patients, 38 (43.7%) exhibited moderate to high work instability (AS-WIS ≥ 11). These patients had higher rates of absenteeism, presenteeism, overall work impair- ment, daily activity impairment, and scores for Ankylosing Spondylitis Disease Activity Score-C Reactive Protein (ASDAS-CRP), Bath Ankylosing Spodylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), The Ankylosing Spondylitis Quality of Life, and PG-VAS. Ankylosing spondylitis patients had an average absence of 10.3 working days in the past year. Their annual healthcare costs averaged €3782.76, primarily due to medication costs of €3674.89. Among the 87 working AS patients, 10 (11%) reported productivity losses in the last year, totaling €1059.62. The AS-WIS score showed moderate to high correlations with presenteeism, daily activity impairment, overall work impairment, BASDAI, PG-VAS, BASFI, and ASDAS-CRP. In contrast, absentee- ism had weak correlations with BASMI and CRP, moderate correlation with overall work impairment, and no correlation with BASDAI and BASFI. Lateral spine mobility, quality of life, educational level, BASFI and BASMI scores, smoking, and the work performed were predictors of work instability and impairment in work productivity.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;In addition to healthcare costs, the costs related to unemployment, absenteeism, and loss of productivity constitute a significant proportion of the total costs, and it was seen that AS has a negative effect on the economy of the country. If","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"12 1","pages":"1-8"},"PeriodicalIF":1.3,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Sacroiliac CT Findings in Patients with Skin Psoriasis, Without Rheumatological Manifestations: A Retrospective Observational Study.","authors":"Thomas Leriche, Olivier Fakih, François Aubin, Mickaël Chouk, Clément Prati, Daniel Wendling, Frank Verhoeven","doi":"10.5152/eurjrheum.2025.24055","DOIUrl":"10.5152/eurjrheum.2025.24055","url":null,"abstract":"<p><strong>Background: </strong>To describe CT characteristics of sacro-iliac joints (SIJs) in patients with psoriasis (PsO) without rheumatological manifestations, and compare them with controls of the same age and sex.</p><p><strong>Methods: </strong>A monocentric, retrospective, observational study was conducted using the medical records of the rheumatology and dermatology departments of the Tertiary Medical Center in France. We included patients with psoriasis, without rheumatological manifestations, who underwent a CT scan including the SIJs. Each patient was matched with an age- and sex-matched control who had undergone a CT scan for rheumatological reasons. CT scan slices were interpreted by two independent rheumatologists, a resident and an expert, using a modified score. Joint space narrowing (JSN), erosions, sclerosis, and intra-articular gas were scored.</p><p><strong>Results: </strong>Sixty patients and 57 controls were included. Global SIJs score was higher in the PsO group (6.63 ± 10.7) than in the control group (2.84 ± 4.87). Erosion and sclerosis did not differ between groups; however, the joint space narrowing score was higher in the PsO group (4.15 ± 10.8 vs. 0.873 ± 4.62, P =.035). There were no correlations between the global score and the disease duration or the severity of psoriasis. The number of gestations, active smoking, alcohol intake, and physical work had no impact on the global score.</p><p><strong>Conclusion: </strong>The CT characteristics of SIJ from patients with PsO were different from those of age- and sex-matched controls, essentially secondary to joint space narrowing.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"12 1","pages":"1-4"},"PeriodicalIF":1.3,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Diagnostic Conundrum: Unusual Presentation of Acute Cutaneous Lupus Erythematosus Mimicking Toxic Epidermal Necrolysis.","authors":"Nilesh Kamble, Rajashree Khot, Saransh Barai, Sachin Chaudhari, Bharatsing Rathod, Onkar Awadhiya","doi":"10.5152/eurjrheum.2025.24030","DOIUrl":"10.5152/eurjrheum.2025.24030","url":null,"abstract":"<p><p>Systemic lupus erythematosus (SLE) is an intricate autoimmune disorder with diverse clinical presentations, encompassing various cutaneous manifestations. This case report describes a diagnostically challenging occurrence of acute cutaneous lupus erythematosus (ACLE) exhibiting a toxic epidermal necrolysis (TEN)-like rash in a 28-year-old female already diagnosed with SLE. The patient's rapid progression from itching to maculopapular skin eruptions involving the face, extremities, and torso within days, coupled with facial puffiness and systemic symptoms, presented a clinical conundrum. Histopathological findings of epidermal hyperkeratosis, acanthosis, and a subcorneal neutrophilic abscess guided the exclusion of other conditions, emphasizing the distinctive features of TEN-like ACLE. The patient exhibited a favorable response to pulse methylprednisolone, mycophenolate mofetil, and hydroxychloroquine.</p>","PeriodicalId":12066,"journal":{"name":"European journal of rheumatology","volume":"12 1","pages":"1-4"},"PeriodicalIF":1.3,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12012747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}